Evaluation of teicoplanin concentrations and safety analysis in neonates

International Journal of Antimicrobial Agents

Volumn 44, Issue 5, 2014, Pages 458-462

  Yamada, Takaaki ^a   Kubota, Toshio ^a,b   Nakamura, Masako ^b   Ochiai, Masayuki ^c   Yonezawa, Mahoro ^b   Yano, Takahisa ^a   Kawashiri, Takehiro ^a   Egashira, Nobuaki ^a,b   Hara, Toshiro ^c   Masuda, Satohiro ^a,b  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Neonates; Safety analysis; Teicoplanin; Therapeutic drug monitoring

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CREATININE; FLUCONAZOLE; TEICOPLANIN; ANTIINFECTIVE AGENT;

ARTICLE; BODY WEIGHT; BONE AND JOINT INFECTIONS; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG SAFETY; ENDOCARDITIS; FEMALE; GESTATIONAL AGE; HUMAN; INCIDENCE; KIDNEY FAILURE; LIVER DYSFUNCTION; LOADING DRUG DOSE; MALE; NEWBORN; OSTEOMYELITIS; RETROSPECTIVE STUDY; STEADY STATE; THROMBOCYTE; THROMBOCYTOPENIA; CHEMICALLY INDUCED; CHEMISTRY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; LIVER FAILURE; PATHOLOGY; SERUM;

ANTI-BACTERIAL AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; LIVER FAILURE; MALE; RENAL INSUFFICIENCY; SERUM; TEICOPLANIN; THROMBOCYTOPENIA;

EID: 84908455019     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.07.005     Document Type: Article

References (15)

1. C.M. Healy, K.G. Hulten, D.L. Palazzi, J.R. Campbell, and C.J. Baker Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit Clin Infect Dis 39 2004 1460 1466
2. C.G. Gemmell, D.I. Edwards, A.P. Fraise, F.K. Gould, G.L. Ridgway, and R.E. Warren Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK J Antimicrob Chemother 57 2006 589 608
3. P.C. Matthews, A. Taylor, I. Byren, and B.L. Atkins Teicoplanin levels in bone and joint infections: are standard doses subtherapeutic? J Infect 55 2007 408 413
4. T. Ueda, Y. Takesue, K. Nakajima, K. Ichki, Y. Wada, and T. Tsuchida Evaluation of teicoplanin dosing designs to achieve a new target trough concentration J Infect Chemother 18 2012 296 302
5. Teicoplanin S.C. Sweetman Martindale: the complete drug reference 36th ed. 2009 The Pharmaceutical Press London, UK 344 345
6. V. Fanos, N. Kacet, and G. Mosconi A review of teicoplanin in the treatment of serious neonatal infections Eur J Pediatr 156 1997 423 427
7. R.F. Frye, M.L. Job, R.H. Dretler, and B.J. Rosenbaum Teicoplanin nephrotoxicity: first case report Pharmacotherapy 12 1992 240 242
8. A.P.R. Wilson, and R. Grunegerg Safety Teicoplanin: the first decade 1997 The Medicine Group (Education) Ltd. Abingdon, UK 137 144
9. M. Seki, K. Yabuno, K. Miyawaki, Y. Miwa, and K. Tomono Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features Clin Pharmacol 4 2012 71 75
10. A. Watanabe, Y. Tokue, N. Aoki, T. Matsumoto, K. Yanagihara, and F. Higa Criteria for safety evaluation of antimicrobial agents J Infect Chemother 17 2011 139 147
11. W.M. Awni, W.L. St Peter, D.R. Guay, M.T. Kenny, and G.R. Matzke Teicoplanin measurement in patients with renal failure: comparison of fluorescence polarization immunoassay, microbiological assay, and high-performance liquid chromatographic assay Ther Drug Monit 13 1991 511 517
12. A. Sánchez, J. López-Herce, E. Cueto, A. Carrillo, and R. Moral Teicoplanin pharmacokinetics in critically ill paediatric patients J Antimicrob Chemother 44 1999 407 409
13. J. Alcorn, and P.J. McNamara Pharmacokinetics in the newborn Adv Drug Delivery Rev 55 2003 667 686
14. T. Kimura, K. Sunakawa, N. Matsuura, H. Kubo, S. Shimada, and K. Yago Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates Antimicrob Agents Chemother 48 2004 1159 1167
15. P.C. Matthews, A.L. Chue, D. Wyllie, A. Barnett, T. Isinkaye, and L. Jefferies Increased teicoplanin doses are associated with improved serum levels but not drug toxicity J Infect 68 2014 43 49